Citation Select	PURPOSE 1 Study Team; Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, Gill K, Harkoo I, Jaggernath M, Kigozi G, Kiwanuka N, Kotze P, Lebina L, Louw CE, Malahleha M, Manentsa M, Mansoor LE, Moodley D, Naicker V, Naidoo L, Naidoo M, Nair G, Ndlovu N, Palanee-Phillips T, Panchia R, Pillay S, Potloane D, Selepe P, Singh N, Singh Y, Spooner E, Ward AM, Zwane Z, Ebrahimi R, Zhao Y, Kintu A, Deaton C, Carter CC, Baeten JM, Matovu Kiweewa F Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women N Engl J Med. 2024 Jul 24. doi: 10.1056/NEJMoa2407001. Epub ahead of print.
Citation Select	Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, Latiff G, Pokrovsky V, Bredeek F, Smith G, Cahn P, Kim YS, Ford SL, Talarico CL, Patel P, Chounta V, Crauwels H, Parys W, Vanveggel S, Mrus J, Huang J, Harrington CM, Hudson KJ, Margolis DA, Smith KY, Williams PE, Spreen WR Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression N Engl J Med. 2020 Mar 4. doi: 10.1056/NEJMoa1904398. [Epub ahead of print]
Citation Select	Orkin C, Arasteh K, Hernández-Mora MG, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D'Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection N Engl J Med. 2020 Mar 4. doi: 10.1056/NEJMoa1909512. [Epub ahead of print]
Citation Select	Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, Edwards A, Bang H, Nicotera J, Godfrey C, Gulick RM, Johnson Jr, Pape JW, Fitzgerald DW Early versus standard antiretroviral therapy for HIV-infected adults in Haiti N Engl J Med. 2010 Jul 15;363(3):257-65
Citation Select	IeDEA Southern and Central Africa, Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis Lancet Infect Dis. 2010 Apr;10(4):251-61
Citation Select	NA-ACCORD Investigators; Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD Effect of early versus deferred antiretroviral therapy for HIV on survival N Engl J Med. 2009 Apr 30;360(18):1815-26
Citation Select	AIDS Clinical Trials Group Study A5142 Team; Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW Class-sparing regimens for initial treatment of HIV-1 infection N Engl J Med. 2008 May 15;358(20):2095-106
Citation Select	Strategies for Management of Antiretroviral Therapy (SMART) Study Group; El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C CD4+ count-guided interruption of antiretroviral treatment N Engl J Med. 2006 Nov 30;355(22):2283-96
Citation Select	RESIST investigator group; Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the RESIST studies: an analysis of combined data from 2 randomised trials Lancet. 2006 Aug 5;368(9534):466-75
Citation Select	AIDS Clinical Trials Group 384 Team; Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection N Engl J Med. 2003 Dec 11;349(24):2304-15
Citation Select	AIDS Clinical Trials Group 384 Team; Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dube MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection N Engl J Med. 2003 Dec 11;349(24):2293-303
Citation Select	064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS; Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schmetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus N Engl J Med. 2003 Aug 28;349(9):837-46
Citation Select	Sophie Grabar, Vincent Le Moing, Cécile Goujard, Catherine Leport, Michel D. Kazatchkine, Dominique Costagliola, and Laurence Weiss Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy Ann Intern Med. 2000 Sep 19;133(6):401-410
Citation Select	Collaborative Group on AIDS Incubation and HIV Survival, including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis Lancet. 2000 Apr 1;355(9210):1131-37
Citation Select	The International Perinatal HIV Group The Mode of Delivery and the Risk of Vertical Transmission of Human Immunodeficiency Virus Type 1. A Meta-Analysis of 15 Prospective Cohort Studies N Engl J Med. 1999 Apr 1;340(13):977-87